No.1
適時開示 適時開示
2026/09/14 18:10
事業の状況
VOLUNTARY ANNOUNCEMENT UPDATED DATA FROM PHASE II CLINICAL STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR NSCLC PRESENTED ORALLY AT WCLC 2026
VOLUNTARY ANNOUNCEMENT UPDATED DATA FROM PHASE II CLINICAL STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR NSCLC PRESENTED ORALLY AT WCLC 2026